Shorter hormone therapy with radiation for high-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether a shorter course of hormone therapy (ADT) combined with radiation is as effective as the standard longer course for men with high-risk prostate cancer that has not spread. It aims to reduce side effects while keeping the cancer under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have been diagnosed with prostate cancer that is considered high-risk but has not spread to lymph nodes or other parts of the body.
- You have not had any prior treatment for prostate cancer, such as surgery, radiation, or hormone therapy.
- Your tumor has a specific genetic marker (PTEN) that is intact, which will be checked by a lab test.
- You are fit enough to undergo radiation and hormone therapy, with adequate blood counts and organ function.
- You have not had a heart attack, unstable angina, or severe heart failure in the past 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a short course of hormone therapy (androgen deprivation therapy) for men with a certain type of prostate cancer that is considered high-risk. The goal is to see if a shorter treatment period can still control the cancer while reducing side effects.
This trial tests whether a shorter course of hormone therapy (2 years) plus a new hormone drug (6 months) with radiation is as effective as longer treatment for high-risk prostate cancer that hasn't spread.
This trial tests a shorter course of radiation therapy with an extra 'boost' to the most aggressive part of the tumor, combined with hormone therapy, for men with high-risk or locally advanced prostate cancer that has not spread outside the pelvis.
This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
Hear when a new High Risk Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.